Z 338

structure in first source

Also Known As:

N-(2-(diisopropylamino)ethyl)-2-((2-hydroxy-4,5-dimethoxybenzoyl)amino)-1,3-thiazole-4-carboxamide; N-(N',N'-diisopropylaminoethyl)-(2-(2-hydroxy-4,5-dimethoxybenzoylamino)-1,3-thiazole-4-yl)carboxyamide; YM 443; YM-443; YM443 cpd; Z-338; acotiamide; acotiamide hydrochloride

Networked: 80 relevant articles (26 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kawabata, Yoshihiro: 7 articles (01/2020 - 03/2011)
2.	Tack, Jan: 7 articles (01/2019 - 03/2011)
3.	Yoshii, Kazuyoshi: 6 articles (01/2020 - 03/2011)
4.	Tack, J: 6 articles (01/2018 - 09/2008)
5.	Hirayama, Masamichi: 5 articles (01/2020 - 09/2011)
6.	Toda, Ryoko: 5 articles (01/2020 - 09/2011)
7.	Takei, Mineo: 4 articles (02/2014 - 03/2011)
8.	Agawa, Shuhei: 3 articles (01/2020 - 01/2018)
9.	Futagami, Seiji: 3 articles (01/2020 - 01/2018)
10.	Hayashi, Yoshikazu: 3 articles (01/2020 - 01/2016)

Related Diseases

1.	Dyspepsia (Indigestion) 06/01/2012 - "Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography." 03/01/2023 - "The patients' symptoms responded quickly to acotiamide, a medication that is effective for treating functional dyspepsia (FD). " 12/01/2017 - "Acotiamide is known as an effective agent for functional dyspepsia. " 06/01/2010 - "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. " 01/01/2018 - "Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial."
2.	Pain (Aches) 01/30/2022 - "Efficacy of acotiamide on postprandial distress syndrome and epigastric pain syndrome depending on the estimated gastric acid secretion level." 01/01/2014 - "Acotiamide improved the symptoms of patients with postprandial distress syndrome (PDS) (RR, 1.29; 95% CI, 1.09-1.53, P = 0.003; I(2) = 0%), and the summary RR for patients with epigastric pain syndrome (EPS) was 0.92 (95% CI, 0.76-1.11, P = 0.39; I(2) = 0%). " 01/01/2018 - "FD-PDS patients (defined by ROME III criteria) aged ≥18 years with active PDS symptoms and without predominant overlapping symptoms of epigastric pain syndrome and related disorders were enrolled to receive 100 mg acotiamide three times daily for 1 year. " 01/01/2016 - "We then evaluated the effect of acotiamide on epigastric pain syndrome (EPS) (n=33) and postprandial distress syndrome (PDS) (n=41). " 01/01/2016 - "The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia."
3.	Heartburn (Pyrosis) 01/01/2020 - "The subjects included 16 FD patients with heartburn who failed PPI treatment, and they were administered acotiamide or a placebo for 28 days. " 01/01/2020 - "Adding acotiamide to PPI therapy appears to improve upper abdominal symptoms in FD patients with heartburn who failed PPI treatment." 01/01/2020 - "In this randomized, double-blind, placebo-controlled crossover study, the effects of adding acotiamide to treatment with proton pump inhibitors (PPI) were investigated in FD patients with heartburn who failed PPI treatment, corresponding to PPI-resistant NERD. " 03/01/2018 - "Acotiamide 300 mg/day in combination with rabeprazole 10 mg/day or rabeprazole 20 mg/day relieved symptoms in patients with overlap between GERD and FD experiencing heartburn and epigastric fullness symptoms after standard-dose PPI for ≥ 8 weeks, and the efficacies did not differ between the two treatments. " 01/01/2020 - "Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study."
4.	Constipation 10/01/2011 - "The results on the safety and efficacy of acotiamide in functional dyspepsia and of linaclotide and prucalopride in idiopathic and IBS-associated constipation were also presented. " 09/01/2016 - "From the therapeutic point of view, more data were presented on the efficacy of acotiamide and its mechanisms of action in functional dyspepsia, the safety and efficacy of domperidone in patients with gastroparesis, and the efficacy of linaclotide both in irritable bowel syndrome and constipation. "
5.	Gastroesophageal Reflux (GERD) 04/30/2018 - "Esophageal peristalsis and esophagogastric junction (EGJ) compliance has an important role for prevention of esophageal mucosal damage caused by gastroesophageal reflux, however, few studies have analyzed the effects of acotiamide on those former activities and none have investigated its effects on EGJ compliance. " 04/30/2018 - "In both healthy individuals and GERD patients, standard dose acotiamide dose does not have significant effects on esophageal motor activities or EGJ compliance." 04/30/2018 - "Similarly in the GERD patients, there were no differences in either esophageal motility or EGJ compliance between before and after acotiamide administration (distensibility index in 40-mL distension: 6.2 ± 0.5 vs 6.5 ± 1.1 mm²/mmHg). " 12/01/2016 - "We report a 44-year-old woman of SSc with severe GERD successfully treated with acotiamide. " 09/11/2015 - "Acotiamide, a novel gastrointestinal motility modulator, at a standard dose did not significantly affect esophageal motor functions or gastroesophageal reflux in healthy adults. "

Related Drugs and Biologics

1.	Z 338
2.	Rabeprazole (Aciphex)
3.	linaclotide
4.	Cholinesterase Inhibitors (Anticholinesterases)
5.	Acetylcholinesterase
6.	Cholinergic Agents (Cholinergics)
7.	1- (5- (2- fluorophenyl)- 1- (pyridin- 3- ylsulfonyl)- 1H- pyrrol- 3- yl)- N- methylmethanamine
8.	Thiazoles
9.	Proton Pump Inhibitors
10.	Esomeprazole (Nexium)

Related Therapies and Procedures

1.	Therapeutics
2.	Gastrectomy
3.	Aftercare (After-Treatment)
4.	Injections
5.	Drug Therapy (Chemotherapy)